Press release from Companies
Publicerat: 2025-04-14 16:27:14
Bio-Works Technologies AB has received an order worth SEK 12 million from a global pharmaceutical company, with delivery scheduled for 2026. The order covers the product WorkBeads affimAb, used for antibody purification in commercial manufacturing processes.
The returning customer has already implemented WorkBeads affimAb in several of its commercial production lines. This new order strengthens the long-term collaboration between the companies and marks the first step toward an expanded partnership.
WorkBeads affimAb is an affinity chromatography resin designed for efficient and selective purification of antibodies, making it an attractive choice for large-scale biopharmaceutical manufacturing.
"We are very proud to receive continued trust from one of the world’s leading pharmaceutical manufacturers. This order is a strong validation of our product’s performance in large-scale, commercial processes – and an important step towards a deeper partnership. It reinforces our position as a strategic supplier to the global biopharmaceutical industry," says Lone Carlbom, CEO of Bio-Works Technologies AB.
This order is a further sign of Bio-Works’ commercial growth and confirms the company’s position as a trusted partner to the global biopharma industry.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 14-04-2025 16:27 CET.
Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, e-mail: lone.carlbom@bio-works.com, phone: +46(0)8-502 705 84.
About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.
Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.